132 related articles for article (PubMed ID: 15709160)
1. Monocyte-derived dendritic cells: a promising armament for immunotherapy in human malignancies.
Yi Q; Kwak LW
Clin Cancer Res; 2005 Feb; 11(3):966-7. PubMed ID: 15709160
[No Abstract] [Full Text] [Related]
2. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells.
Tokunaga N; Murakami T; Endo Y; Nishizaki M; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2005 Feb; 11(3):1312-8. PubMed ID: 15709203
[TBL] [Abstract][Full Text] [Related]
3. Tumor-dendritic cell fusion technology and immunotherapy strategies.
Shu S; Cohen P
J Immunother; 2001; 24(2):99-100. PubMed ID: 11265778
[No Abstract] [Full Text] [Related]
4. The therapeutic role of dendritic cells in cancer immunotherapy.
Lemoli RM; Curti A; Fogli M; Ferri E; Baccarani M
Haematologica; 2002 Aug; 87(8 Suppl):62-6. PubMed ID: 12412393
[No Abstract] [Full Text] [Related]
5. Dendritic cell based immunotherapy--a promising therapeutic approach for endocrine malignancies.
Sbiera S; Wortmann S; Fassnacht M
Horm Metab Res; 2008 Feb; 40(2):89-98. PubMed ID: 18283626
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells that endocytosed antigen-containing IgG-liposomes elicit effective antitumor immunity.
Kawamura K; Kadowaki N; Suzuki R; Udagawa S; Kasaoka S; Utoguchi N; Kitawaki T; Sugimoto N; Okada N; Maruyama K; Uchiyama T
J Immunother; 2006; 29(2):165-74. PubMed ID: 16531817
[TBL] [Abstract][Full Text] [Related]
7. Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy.
Ueda Y; Itoh T; Fuji N; Harada S; Fujiki H; Shimizu K; Shiozaki A; Iwamoto A; Shimizu T; Mazda O; Kimura T; Sonoda Y; Taniwaki M; Yamagishi H
Cancer Immunol Immunother; 2007 Mar; 56(3):381-9. PubMed ID: 16830156
[TBL] [Abstract][Full Text] [Related]
8. Are dysfunctional monocyte-derived dendritic cells in cancer an explanation for cancer vaccine failures?
Barbuto JA
Immunotherapy; 2013 Feb; 5(2):105-7. PubMed ID: 23413899
[No Abstract] [Full Text] [Related]
9. Dendritic cell immunotherapy for stage IV melanoma.
O'Rourke MG; Johnson MK; Lanagan CM; See JL; O'Connor LE; Slater GJ; Thomas D; Lopez JA; Martinez NR; Ellem KA; Schmidt CW
Melanoma Res; 2007 Oct; 17(5):316-22. PubMed ID: 17885587
[TBL] [Abstract][Full Text] [Related]
10. [Cancer immunotherapy using dendritic cells: current status and perspective].
Okano S; Yonemitsu Y; Sueishi K
Fukuoka Igaku Zasshi; 2007 Jul; 98(7):277-86. PubMed ID: 17710892
[No Abstract] [Full Text] [Related]
11. The hybrid cell vaccination approach to cancer immunotherapy.
Trefzer U; Herberth G; Sterry W; Walden P
Ernst Schering Res Found Workshop; 2000; (30):154-66. PubMed ID: 10943322
[No Abstract] [Full Text] [Related]
12. Cancer therapy-induced immune modulation.
Karl JC; Mackall CL
Cancer Chemother Biol Response Modif; 2005; 22():325-41. PubMed ID: 16110619
[No Abstract] [Full Text] [Related]
13. Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes.
Tanaka F; Yamaguchi H; Haraguchi N; Mashino K; Ohta M; Inoue H; Mori M
Int J Oncol; 2006 Nov; 29(5):1263-8. PubMed ID: 17016660
[TBL] [Abstract][Full Text] [Related]
14. Adhesion of monocyte-derived dendritic cells to human umbilical vein endothelial cells in flow field decreases upon maturation.
Jiang Y; Zeng Z; Sun D; Ka W; Wen Z
Clin Hemorheol Microcirc; 2005; 32(4):261-8. PubMed ID: 15894824
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell immunotherapy for the treatment of neoplastic disease.
Decker WK; Xing D; Shpall EJ
Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
[TBL] [Abstract][Full Text] [Related]
16. Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendritic cells for dendritic cell-based immunotherapy.
Hayden H; Friedl J; Dettke M; Sachet M; Hassler M; Dubsky P; Bachleitner-Hofmann T; Gnant M; Stift A
J Immunother; 2009; 32(6):638-54. PubMed ID: 19483645
[TBL] [Abstract][Full Text] [Related]
17. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy.
Dullaers M; Thielemans K
J Gene Med; 2006 Jan; 8(1):3-17. PubMed ID: 16288497
[TBL] [Abstract][Full Text] [Related]
18. Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma.
Goto S; Kaneko T; Miyamoto Y; Eriguchi M; Kato A; Akeyama T; Fujimoto K; Tomonaga M; Egawa K
Anticancer Res; 2005; 25(6A):3741-6. PubMed ID: 16302734
[TBL] [Abstract][Full Text] [Related]
19. T-cadinol and calamenene induce dendritic cells from human monocytes and drive Th1 polarization.
Takei M; Umeyama A; Arihara S
Eur J Pharmacol; 2006 May; 537(1-3):190-9. PubMed ID: 16631732
[TBL] [Abstract][Full Text] [Related]
20. Cell fusion: from hybridoma to dendritic cell-based vaccine.
Gong J; Koido S; Calderwood SK
Expert Rev Vaccines; 2008 Sep; 7(7):1055-68. PubMed ID: 18767954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
